Related Experiment Video
Updated: May 20, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
Poly (ε-caprolactone) coating delays vancomycin delivery from porous chitosan/β-tricalcium phosphate composites
Taolin Fang1, Jianchuan Wen, Jian Zhou
1Department of Orthopaedic Surgery, Zhongshan Hospital, State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai 200032, China.
Abstract:
The orthopedic infection, such as osteomyelitis, especially those caused by Methicillin-resistant Staphylococcus aureus (MRSA), remains a major complication of open fractures. Local vancomycin delivery is considered to provide better methods when avascular zones prevent the delivery of drugs from conventional routes of administration. Chitosan (CS) delivery system has been developed with the disadvantages, such as mechanically weakness, lacking osteoconductivity, and the initial burst of antibiotics into the environment. The aim of this study was to confirm that the prepared CS/β-tricalcium phosphate (β-TCP) composites coated with poly (ε-caprolactone) (PCL), similar to natural bone in components, had a three-dimensional porous structure and could be used as drug carriers to deliver vancomycin in a sustained and controlled manner effectively for 6 weeks at levels to inhibit MRSA proliferation. We prepared porous CS/β-TCP composites by incorporating β-TCP into the system, and coated the composites with PCL of three different concentrations. The morphological structure of composites, including pore size and porosity, was examined. The result showed that CS/β-TCP coated with 2.5w/v% PCL solution had the best coating effect and it retarded the release of vancomycin in a near zero-order mechanism from 0 to 14 days. The drug delivery was significantly delayed after coated with 2.5w/v% PCL. The quantitative release of vancomycin was extended to 42 days. Therefore PCL coating could be used to retard the release of vancomycin from CS/β-TCP composites in a sustained and controlled manner. Porous CS/β-TCP coated with PCL might be one of the candidate vancomycin carriers for treating MRSA-related osteomyelitis.
Insights
This study developed a novel chitosan/β-tricalcium phosphate composite coated with poly(ε-caprolactone) for sustained vancomycin delivery. This system effectively inhibits Methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis for six weeks.
Area of Science:
- Biomaterials Science
- Orthopedic Surgery
- Infectious Diseases
Background:
- Osteomyelitis, particularly MRSA infections, is a significant complication of open fractures.
- Conventional antibiotic delivery faces challenges in avascular bone zones.
- Existing chitosan (CS) drug delivery systems have limitations like mechanical weakness and burst release.
Purpose of the Study:
- To evaluate CS/β-tricalcium phosphate (β-TCP) composites coated with poly(ε-caprolactone) (PCL) as sustained vancomycin drug carriers.
- To confirm the composite's suitability for treating MRSA-related osteomyelitis.
- To assess the impact of PCL coating on vancomycin release kinetics.
Main Methods:
- Prepared porous CS/β-TCP composites incorporating β-TCP.
- Coated composites with varying concentrations of PCL.
- Examined composite morphology, pore size, and porosity.
- Quantified vancomycin release over 42 days.
Main Results:
- CS/β-TCP composites coated with 2.5w/v% PCL exhibited optimal coating.
- PCL coating significantly retarded vancomycin release, extending it to 42 days.
- Release kinetics followed a near zero-order mechanism from 0 to 14 days.
Conclusions:
- PCL coating effectively controls and sustains vancomycin release from CS/β-TCP composites.
- Porous CS/β-TCP composites coated with PCL are promising carriers for MRSA osteomyelitis treatment.
- This composite system offers a potential solution for localized antibiotic delivery in challenging orthopedic infections.
Related Concept Videos
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Oral Drug Delivery Systems: Delayed-Release Systems
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Oral Drug Delivery Systems: Continuous-Release Systems
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Modified-Release Drug Delivery Systems: Site-Targeted
